Hypertension and the cardiometabolic syndrome in Chile: A review of concepts and consequences for the developing world

Therapeutic Advances in Cardiovascular Disease

Volumn 1, Issue 1, 2007, Pages 83-90

  Margozzini, Paula ^a   Rigotti, A ^a   Ferreccio, C ^a   Quezada, N ^a   Garrido, M ^a   Valdes G ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cardiometabolic Syndrome; Cardiovascular Disease; Cardiovascular Risk; Epidemiology; Hypertension; Metabolic Syndrome

Indexed keywords

CHILE; DEVELOPING COUNTRY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; STATISTICS; ADULT; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH SURVEY; IMMOBILIZATION; INDIVIDUALIZATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; OBESITY; PATIENT CARE; POVERTY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SMOKING CESSATION; URBAN RURAL DIFFERENCE;

CHILE; DEVELOPING COUNTRIES; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; INSULIN;

EID: 40849123312     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944707082716     Document Type: Review

References (46)

1. Aguilar-Salinas, C.A. et al. (2004) High Prevalence of Metabolic Syndrome in Mexico. Arch Med Res 35: 76–81.
2. Alberti, K.G. and Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–555.
3. Arcaro, G. et al. (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105: 576–582.
4. Balkau, B. and Charles, M.A. (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16: 442–453.
5. Bergman, R.N. et al. (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120(2 Suppl 1): S3–S8
6. Cuspidi, C. et al. (2007) Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 20: 296–303.
7. de Fronzo, R.A. et al. (1975) The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 55: 845–855.
8. Despres, J.P. (2006) Is visceral obesity the cause of the metabolic syndrome? Ann Med 38: 52–63.
9. Despres, J.P. and Lemieux, I. (2006) Abdominal obesity and metabolic síndrome. Nature 444: 881–887.
10. Eckel, R.H. et al. (2005) The metabolic síndrome. Lancet 365: 1415–1428.
11. Einhorn, D. et al. (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9: 237–252.
12. Fasce, E. et al. (1992) La hipertensión arterial en una comunidad urbana de Chile. Rev Chil Cardiol 11: 1–12.
13. Ferrario, C.M. et al. (2002) The hypertension–lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 323: 17–24.
14. Grundy, S.M. et al. (2004) American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related to definition. Circulation 109: 433–438.
15. Guo, X. ( 2005) Hypertension genes are genetic markers for insulin sensitivity and resistance. Hypertension 45: 799–803.
16. Hall, J.E. et al. (1992) Obesity–associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension 19(1 Suppl): 145–155.
17. International Diabetes Federation (2005) The IDF consensus worldwide definition of the metabolic syndrome. Part 1: Worldwide definition for use in clinical practice. Available at http://www.idf.org/webdata/docs/Metabolic_Syndrome_Definition.pdf.
18. Kahn, R. et al. (2005) American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289–2330.
19. Kaplan, N.M. (1989) The deadly quartet. Upper–body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149: 1514–1522.
20. Kempf, K. et al. (2006) Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann NY Acad Sci 1084: 30–48.
21. Kershaw, E.E. and Flier, J.S. (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548–56.
22. Kintschner, U. et al. (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Cardiovasc Diabetol 36: 12.
23. Kjeldsen, S.E. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high–risk hypertensive patients: the VALUE trial. J Hypertens 24: 1405–1412.
24. Kunze, D.L. et al. (2007) Hypertension in sleep apnea: the role of the sympathetic pathway. Cleve Clin J Med 74: S34–S36
25. Lee, Y.H. and Pratley, R.E. (2005) The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 5: 70–75.
26. Leslie, B.R. (2005) Metabolic syndrome: historical perspectivas. Am J Med Sci 330: 264–268.
27. Meisinger, C. et al. (2006) Metabolic syndrome: older than usually assumed, but still too young to die. Clin Chem 52: 897–898.
28. Minsal (2003) Encuesta Nacional de Salud, Chile 2003. Available at: http://epi.minsal.cl/epi/html/invest/ENS/ENS.htm.
29. National Cholesterol Education Program (2001 ) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001) J Am Med Assoc 285: 2486–2497.
30. Negro, R. et al. (2004) Pioglitazone reduces blood pressure in non–dipping diabetic patients. Minerva Endocrinol 29: 11–17.
31. Negro, R. et al. (2005) Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 70: 20–25.
32. Ong, K.L. et al. (2007) Prevalence, Awareness, Treatment, and Control of Hipertensión Among United Status Adults 1999–2004. Hypertension 49: 69–75.
33. Raikkonen, K. et al. (2007) Depressive symptoms and stressful life events predict metabolic syndrome among middle–aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care 30: 872–877.
34. Reaven, G. (1988) Role of insulin resistance in human disease. Diabetes 37: 1595–1607.
35. Reaven, G.M. (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44: 121–123.
36. Reaven, G.M. (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473–486.
37. Reaven, G.M. (2005) The metabolic syndrome: requiescat in pace. Clin Chem 51: 931–938.
38. Reaven, G.M. (2006) The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83: 1237–1247.
39. Roberts, A.W. and Evans, M. (2004) The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetes. Curr Opin Lipidol 15: 89–91.
40. Sarafidis, P.A. and Nilsson, P.M. (2006) The metabolic syndrome: a glance at its history. J Hypertens 24: 621–626.
41. Simons, L.A. et al. (1998) Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 137: 197–203.
42. Stout, R.W. (1991) Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med 90: 62S–65S.
43. Stout, R.W. (1992) Insulin and atherogenesis. Eur J Epidemiol (Suppl 1): 134–135.
44. Thomas, G.N. et al. (2000) Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism 49: 1523–1528.
45. WHO Collaborating Centre for Drug Statistics Methodology (2007) Available at: http://www.whocc.no/atcddd/atcsystem.html.
46. Wofford, M.R. et al. (2004) Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 10: 3621–3637.